Skip to main content

Table 3 Associations between genetically predicted urate, baseline FEV1 and lung cancer incidence

From: Serum urate and lung cancer: a cohort study and Mendelian randomization using UK Biobank

 

Coefficient per 100 µmol serum urate*

p value

Coefficient per 100 µmol serum urate*

p value

Incidence change per 10,000 PYs

FEV1 (ml)

IRR lung cancer

Overall

− 10.5 (− 23 to 2.1)

0.10

0.88 (0.68–1.14)

0.33

− 0.98 (− 2.95 to 1.00)

Never

− 12.3 (− 28.5 to 3.9)

0.14

0.88 (0.42–1.85)

0.74

− 0.25 (− 1.76 to 1.26)

Former

− 12.0 (− 32.9 to 8.9)

0.26

0.86 (0.59–1.26)

0.43

− 1.36 (− 4.75 to 2.03)

Current

11.0 (− 32.9 to 55.0)

0.62

0.91 (0.61–1.34)

0.62

− 3.40 (− 17.01 to 10.21)

Overall regular

− 5.0 (− 28.9 to 18.8)

0.68

0.88 (0.66–1.18)

0.40

− 2.43 (− 8.09 to 3.24)

Light former

− 14.3 (− 50.7 to 22.2)

0.44

1.60 (0.69–3.70)

0.27

3.63 (− 2.83 to 10.08)

Heavy former

− 17.6 (− 54.0 to 18.8)

0.34

0.68 (0.42–1.10)

0.12

− 6.11 (− 13.73 to 1.52)

Current light

15.9 (− 43.5 to 75.3)

0.60

1.00 (0.54–1.86)

1.00

0.05 (− 23.32 to 23.43)

Current heavy

40.9 (− 37.7 to 119.4)

0.31

0.56 (0.31–1.00)

0.05

− 39.10 (− 78.36 to 0.16)

  1. IRR incidence rate ratio
  2. *Adjusted for sex, age, calendar year, ethnicity (first 40 principal components) and recruitment centre